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Abstract
Little is known about the interaction between Streptococcus pneumoniae and Staphylococcus aureus in school-age 
children and adolescents suffering from an underlying chronic disease. To increase our knowledge in this regard, an 
oropharyngeal swab was obtained from school-age children and adolescents suffering from asthma (n = 423), cystic 
fibrosis (CF) (n = 212) and type 1 diabetes mellitus (DM1) (n = 296). S. pneumoniae detection and serotyping were 
performed using a real-time polymerase chain reaction, and S. aureus detection was performed using the RIDAGENE 
MRSA system. Among asthmatic, CF and DM1 patients, both pathogens were identified in 65/423 (15.4%), 21/212 
(9.9%) and 62/296 (20.9%) children, respectively; S. pneumoniae alone was identified in 127/434 (30.0%), 21/212 (9.9%) 
and 86/296 (29.1%), respectively; S. aureus alone was identified in 58/434 (13.7%), 78/212 (36.8%) and 49/296 (16.6%), 
respectively. S. pneumoniae colonisation rates were higher in younger children and declined with age, whereas the 
frequency of S. aureus colonisation was quite similar in the different age groups. Among asthmatic and CF patients 
aged 6–9 years, S. aureus carriage was significantly higher in children who were positive for S. pneumoniae (P <0.05). 
No significant association emerged between S. aureus carriage and carriage of S. pneumoniae serotypes included in the 
pneumococcal conjugate vaccines (PCVs). This study shows for the first time that school-age children and adolescents 
with asthma, CF and DM1 are frequently colonised by S. pneumoniae and S. aureus and that no negative relationship 
seems to exist between these pathogens. Moreover, the supposed protection offered by PCV administration against S. 
aureus colonisation was not demonstrated.
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Introduction
The upper respiratory tract is the reservoir of a 
diverse community of commensal and potential 
pathogens. Pharyngeal colonisation is a dynamic 
process that in a balanced state has a major benefi-
cial role for the human host.1 However, an imbal-
ance of the respiratory microbial community can 
be the basis for developing invasive and mucosal 
diseases due to an overgrowth of pre-existing path-
ogens or the acquisition of new infectious agents. 
Streptococcus pneumoniae and Staphylococcus 
aureus are common commensals of the upper res-
piratory tract and among the major causes of bacte-
rial infections in infants and children when 
imbalance occurs.2,3 A better understanding of the 
incidence of carriage and the relationship between 
these two pathogens, including their potential for 
mutual interference, is needed to evaluate the epi-
demiology of the disease caused by each of them 
and the impact of related preventative measures, 
including the pneumococcal conjugate vaccines 
(PCVs).
A number of studies have investigated the co-
colonisation of both healthy and ill children by 
S. pneumoniae and S. aureus, but these studies have 
reported conflicting results.4–8 However, most of 
these studies were carried out in healthy younger 
children.9 Little is known about the interaction 
between these pathogens in school-age children and 
adolescents suffering from an underlying chronic 
disease although in some cases an increased risk of 
pneumococcal or staphylococcal infection in 
patients with asthma10 or cystic fibrosis (CF)11 is 
well known. Moreover, no data are available on the 
impact of vaccination with PCVs, given several 
years before, on combined S. pneumoniae and 
S. aureus colonisation of these subjects. To increase 
our knowledge in this regard, a study specifically 
designed to evaluate pneumococcal and staphylo-
coccal pharyngeal colonisation rates in school-age 
children and adolescents suffering from asthma, CF 
and type 1 diabetes mellitus (DM1) was carried out.
Materials and methods
Swab collection
During the period 1 January 2014 to 30 June 2014, 
this study enrolled children and adolescents (age 
range, 6–17 years) suffering from documented 
asthma, CF and DM1 regularly followed in the 
outpatient clinic of the University of Milan’s 
Department of Pathophysiology and Transplantation 
and in a number of Department of Pediatrics sited 
in Pavia, Modena, Verona, Rome and Naples. The 
protocol was approved by the Ethics Committees 
of each participating centre. Moreover, written 
informed consent was obtained from the parent(s) 
or legal guardian(s) of each study participant and 
from participants aged older than 8 years. In asth-
matic children, the characteristics of asthma were 
evaluated on the basis of the Global Initiative for 
Asthma criteria.12 Only clinically stable patients 
with mild to moderate disease were considered 
suitable for enrolment. Subjects with CF had to be 
free from acute respiratory exacerbation. Finally, 
DM1 patients had to be in good metabolic equilib-
rium. All patients were clinically stable at the time 
of enrolment; patients with active respiratory infec-
tion, those with a chronic underlying disease other 
than those in the study, and those who had received 
antibiotic therapy during the previous 2 weeks 
were excluded. Data regarding the medical history 
of each subject, including vaccination, were col-
lected by means of a questionnaire that was com-
pleted by parents/guardians for children <15 years 
and by the adolescents themselves for those ⩾15 
years. Children were considered fully vaccinated 
against S. pneumoniae if they have received three 
doses of the heptavalent pneumococcal conjugate 
vaccine (PCV7) in the first year of life or two doses 
in the second year or a single dose after the second 
until the age of 5 years, according to the recom-
mendations of the Italian Ministry of Health (http://
www.salute.gov.it/portale/documentazione/
p6_2_2_1.jsp?lingua=italiano&id=543).
In each centre, swabbing was carried out by a 
group of experienced paediatric nurses supervised 
by a paediatrician. The collection of pharyngeal 
secretions was performed by means of an oro-
pharyngeal swab because recent studies have sug-
gested that oropharyngeal samples are better for 
determining S. pneumoniae carrier status in school-
age children and adolescents13 and may give infor-
mation regarding S. aureus colonisation rates not 
substantially different from those determined by 
traditional anterior nares samples.13
Oropharyngeal swabs were obtained using the 
ESwab kit and a polypropylene screw-cap tube 
with an internal conical shape filled with 1 mL liq-
uid Amies medium (cat. Number 480CE, Brescia, 
Copan, Italy). Sampling was carried out using a 
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tongue spatula to press the tongue downward to 
floor of the mouth and swabbing both the tonsillar 
arches and the posterior pharynx, without touching 
the sides of the mouth. All swabs were immedi-
ately transported to a central laboratory and pro-
cessed within 2 h for the identification of S. 
pneumoniae and S. aureus.
S.pneumoniae and S. aureus identification
For S. pneumoniae identification, bacterial genomic 
DNA was directly extracted from the samples 
using a NucliSENS easyMAG automated extrac-
tion system (BioMeriéux, Bagno a Ripoli, Florence, 
Italy), a 250 µL sample input and a generic proto-
col and was tested for the autolysin-A-encoding 
gene (lytA) and the wzg (cpsA) gene of S. pneumo-
niae by means of real-time PCR (RT-PCR) as pre-
viously described.14 Each sample was tested in 
triplicate and was considered positive if at least 
two of the three tests revealed the presence of both 
genes. The level of detection of the test was 16 
genome copies. All positive cases were serotyped 
using primers and probes designed on the basis of 
the GenBank database sequences (www.ncbi.nlm.
nih.gov) of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F and 23F (i.e. those in the 13-valent 
pneumococcal conjugate vaccine [PCV13]) and 
synthesised by TIB Molbiol (Genoa, Italy) as pre-
viously described.14 Analytical specificity was pre-
evaluated by means of computer-aided analyses 
using Primer-BLAST (www.ncbi.nlm.nih.gov/
tools/primer-blast) and BLAST (www.blast.ncbi.
nlm.nih.gov/Blast.cgi) software to compare the 
sequences with all listed ‘bacteria’ and ‘homo sapi-
ens’ sequences.
S. aureus was identified using the RIDAGENE 
MRSA system (R-Biopharm AG, Darmstadt, 
Germany). The RIDAGENE MRSA system is a 
multiplex real-time PCR for the direct, qualitative 
detection and differentiation of methicillin-resistant 
S. aureus (MRSA) and methicillin-sensitive S. 
aureus (MSSA). An internal control is added to the 
samples during extraction to determine possible 
PCR inhibition or DNA extraction failure. After 
DNA isolation, the mecA/mecC gene, SCCmec/orfX 
junction (type I, II, III, IV, V, VI, VII, IX and XI) and 
the orfX gene are amplified by TaqMan according to 
the manufacturer’s instructions using the Agilent 
Stratagene Mx3005P real-time PCR platform. The 
samples were evaluated as follows: negative, no 
amplification signal but internal control DNA posi-
tive; MRSA, positive for mecA/mecC, the 
SCCmec/orfX junction, and orfX; MSSA, positive 
for both the SCCmec/orfX junction and orfX or only 
orfX. The RIDAGENE MRSA system has a limit of 
detection of ⩽5 DNA copies per reaction.
Statistical analysis
A contingency table analysis with the chi-squared 
or Fisher’s exact test, as appropriate, was used to 
compare differences between groups. For an easier 
evaluation of carriage modifications in the studied 
population, this was arbitrarily subdivided into 
three age groups (6–9 years, 10–14 years and ⩾15 
years). Subgroup analyses were performed based 
on age and PCV7 vaccination status. All tests were 
two-sided, and a P value <0.05 was considered sta-
tistically significant. Data were analysed using 
SAS, version 9.2 (SAS Institute, Cary, NC, USA).
Results
Asthmatic patients
The study enrolled 423 participants with asthma 
(70.9% boys; median age, 10.6 years). Among 
them 176 (41.6%) were aged between 6 and 9 
years, 207 (48.9%) were aged between 10 and 14 
years and 40 (9.5%) were aged ⩾15 years. The car-
riage of S. pneumoniae and S. aureus according to 
age and PCV7 vaccination coverage is shown in 
Table 1. A total of 173 (40.9%) patients did not 
carry either S. pneumoniae or S. aureus. Both path-
ogens were identified in 65 (15.4%) children, S. 
pneumoniae alone and S. aureus alone in 127 
(30.0%) and 58 (13.7%), respectively. S. pneumo-
niae colonisation rates were higher in younger 
children and declined with age (52.8% in children 
aged 6–9 years, 43.5% in those aged 10–14 years 
and 22.5% in those aged ⩾15 years). In contrast, 
the frequency of S. aureus colonisation was quite 
similar in all age groups (27.8%, 30.4% and 27.5% 
in children aged 6–9 years, 10–14 years, and ⩾15 
years, respectively). S. aureus carriage was signifi-
cantly higher in children who were positive for 
S. pneumoniae (65/192, 33.9% vs. 58/231, 25.1%; 
P = 0.049). However, when carriage was evaluated 
according to the age of enrolled children, it was 
found that this difference remained statistically 
significant only for children aged 6–9 years (32/93, 
34.4% vs. 17/83, 20.5%; P = 0.04).
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Table 1. Oropharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in 423 asthmatic children, according to 
selected subgroups and S. pneumoniae serotypes.
S. pneumonia S. aureus P value
 Negative Positivea  
n (row %) n (row %)
All subjects  
Negative 173 (74.9) 58 (25.1)  
Positive 127 (66.1) 65 (33.9) 0.049
Age subgroups  
6–9 years (n = 176)  
Negative 66 (79.5) 17 (20.5)  
Positive 61 (65.6) 32 (34.4) 0.04
10–14 years (n = 207)  
Negative 85 (72.6) 32 (27.4)  
Positive 59 (65.6) 31 (34.4) 0.27
15–17 years (n = 40)  
Negative 22 (71.0) 9 (29.0)  
Positive 7 (77.8) 2 (22.2) 0.99
Vaccination with PCV7  
Unvaccinated (n = 228)  
Negative 93 (72.1) 36 (27.9)  
Positive 67 (67.7) 32 (32.3) 0.47
Vaccinated (n = 195)  
Negative 80 (78.4) 22 (21.6)  
Positive 60 (64.5) 33 (35.5) 0.03
Serotypes of PCV7b  
Positive for any PCV7 serotype 119 (66.5) 60 (33.5)  
Negative for PCV7 serotypes, 
but positive for S. pneumonia
8 (61.5) 5 (38.5) 0.77
Serotypes of PCV13b  
Positive for any PCV13 serotype 119 (65.4) 63 (34.6)  
Negative for PCV13 serotypes, 
but positive for S. pneumonia
8 (80.0) 2 (20.0) 0.50
Specific serotypesc  
Negative for serotype 3 283 (70.7) 117 (29.3)  
Positive for serotype 3 17 (73.9) 6 (26.1) 0.75
Negative for serotype 4 255 (71.2) 103 (28.8)  
Positive for serotype 4 45 (69.2) 20 (30.8) 0.74
Negative for serotype 5 277 (71.9) 108 (28.1)  
Positive for serotype 5 23 (60.5) 15 (39.5) 0.14
Negative for serotype 6A 296 (71.8) 116 (28.2)  
Positive for serotype 6A 4 (36.4) 7 (63.6) 0.02
Negative for serotype 9V 274 (71.5) 109 (28.5)  
Positive for serotype 9V 26 (65.0) 14 (35.0) 0.39
Negative for serotype 19A 296 (71.7) 117 (28.3)  
Positive for serotype 19A 4 (40.0) 6 (60.0) 0.07
Negative for serotype 19F 189 (73.8) 67 (26.2)  
Positive for serotype 19F 111 (66.5) 56 (33.5) 0.10
a Among S. aureus cases, 95.4% were methicillin-sensitive and 4.6% methicillin-resistant. Seven patients were positive for staphylococcal cassette 
chromosome mec.
bAmong 192 subjects positive for S. pneumoniae.
c Only serotypes of S. pneumoniae for which at least 10 subjects were positive are presented in the table.
PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
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Among vaccinated subjects, S. aureus was iden-
tified more frequently in children who were posi-
tive for S. pneumoniae than in those who were 
negative (33/93, 35.5% vs. 22/102, 21.6%; P = 
0.03). In contrast, among unvaccinated subjects, 
the percentage of those colonised by S. aureus was 
not materially different in subjects positive and 
negative for S. pneumoniae (32/99, 32.3% vs. 
36/129, 27.9%, P = 0.47). Among 192 subjects 
positive for S. pneumoniae, no significant associa-
tion emerged between S. aureus carriage and car-
riage of S. pneumoniae serotypes included in PCV7 
(P = 0.77) nor PCV13 (P = 0.50).
CF patients
A total of 212 CF patients were enrolled (48.1% 
boys; median age, 11.7 years). Among them, 63 
(29.7%) were aged 6–9 years, 102 (48.1%) were 
aged 10–14 years and 47 (22.2%) were aged ⩾15 
years. The carriage of S. pneumoniae and S. 
aureus according to age and PCV7 vaccination 
coverage is shown in Table 2. A great number of 
patients were not colonised by the studied patho-
gens (92, 43.4%). Both pathogens were identified 
in 21 (9.9%) children, S. pneumoniae alone and S. 
aureus alone in 21 (9.9%) and 78 (36.8%), respec-
tively. S. pneumoniae colonisation rates were 
higher in younger children and declined with age 
(28.6% in children aged 6–9 years, 17.6% in those 
aged 10–14 years and 12.8% in those aged ⩾15 
years). The frequency of S. aureus colonisation 
was slightly higher in children aged 10–14 years 
(51/102, 50.0%) in comparison with patients aged 
6–9 years and ⩾15 years (29/63, 46.0% and 
19/47, 40.4%, respectively). S. aureus carriage 
was quite similar in children positive and nega-
tive for S. pneumoniae (21/42, 50.0% vs. 78/170, 
45.9%; P = 0.63). However, in younger children, 
colonisation by S. aureus was significantly higher 
in patients positive for S. pneumoniae than in 
those who were negative (12/18, 66.6% vs. 17/45, 
37.8%; P = 0.04).
Among vaccinated subjects, S. aureus was iden-
tified with similar frequency in children who were 
positive and negative for S. pneumoniae (3/10, 
30.0% vs. 10/25, 40.0%; P = 0.71). Similarly, 
among unvaccinated subjects, the percentage of 
those colonised by S. aureus was not materially 
different in subjects positive and negative for 
S. pneumoniae (18/32, 56.3% vs. 68/145, 46.9%; 
P = 0.34).
Among 42 subjects positive for S. pneumoniae, 
no significant association emerged between S. 
aureus carriage and carriage of the PCV7 and 
PCV13 S. pneumoniae serotypes, although the 
number of subjects positive for serotypes other 
than PCV7 was small (n = 3).
Diabetic patients
A total of 296 DM1 patients were enrolled (51.3% 
boys; median age, 12.7 years). Among them, 61 
(20.6%) were aged 6–9 years, 154 (52.0%) were 
aged 10–14 years and 81 (27.4%) were aged ⩾15 
years. The carriage of S. pneumoniae and S. aureus 
according to age and PCV7 vaccination coverage 
is shown in Table 3. Approximately one-third of 
the patients were not colonised by the studied bac-
teria (99, 33.4%). Both pathogens were identified 
in 62 (20.9%) children, and S. pneumoniae alone 
and S. aureus alone were identified in 86 (29.1%) 
and 49 (16.6%), respectively. S. pneumoniae colo-
nisation rates were higher in younger children and 
declined with age (62.3% in children aged 6–9 
years, 53.9% in those aged 10–14 years and 33.3% 
in those aged ⩾15 years). The frequency of S. 
aureus colonisation was quite similar in the three 
age groups even if slightly higher in children aged 
6–9 years (25/61, 41.0%) in comparison with 
patients aged 10–14 years and ⩾15 years (56/154, 
36.4% and 30/81, 37.0%, respectively). S. aureus 
carriage was not significantly different between 
children positive and negative for S. pneumoniae 
(62/148, 41.9% vs. 49/148, 33.1%; P = 0.12), even 
when different age groups were considered.
Among vaccinated subjects, S. aureus was identi-
fied more frequently in children who were positive 
for S. pneumoniae than those who were negative 
(26/56, 46.4% vs. 14/53, 26.4%; P = 0.03). In con-
trast, among unvaccinated subjects, the percentage 
of those colonised by S. aureus was similar in sub-
jects positive and negative for S. pneumoniae (35/88, 
39.8% vs. 32/86, 37.2%; P = 0.73).
Among 148 subjects positive for S. pneumoniae, 
no significant association emerged between S. 
aureus carriage and carriage of the PCV7 and 
PCV13 S. pneumoniae serotypes, although the 
number of subjects positive for serotypes other 
than PCV7 was small (n = 4).
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Discussion
Whether bacteria can colonize or not is determined 
by many ecological factors including the availa-
bility of resources (i.e. nutrients, space, attach-
ment space), host immune responses and the 
presence of toxins or harmful substances.15 
Moreover, the interference between bacterial resi-
dent populations producing harmful substances 
(i.e. bacterocins)15,16 or inducing an immune 
response17,18 can play a role at this regard. In the 
case of S. pneumoniae and S. aureus, epidemio-
logical studies showed that co-colonisation is rarer 
than expected and suggested that S. pneumoniae 
colonisation is reduced in presence of S. pneumo-
niae.19,20 Knowledge of carriage characteristics of 
these pathogens, which is important in healthy 
children, is even more relevant in subjects with 
chronic underlying disease because applicable 
Table 2. Oropharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in 212 children with cystic fibrosis, also 
according to selected subgroups and Streptococcus pneumoniae serotypes.
S. pneumoniae S. aureus P value
 Negative Positivea  
n (row %) n (row %)
All subjects  
Negative 92 (54.1) 78 (45.9)  
Positive 21 (50.0) 21 (50.0) 0.63
Age subgroups  
6–9 years (n = 63)  
Negative 28 (62.2) 17 (37.8)  
Positive 6 (33.3) 12 (66.7) 0.04
10–14 years (n = 102)  
Negative 40 (47.6) 44 (52.4)  
Positive 11 (61.1) 7 (38.9) 0.30
15–17 years (n = 47)  
Negative 24 (58.5) 17 (41.5)  
Positive 4 (66.7) 2 (33.3) 0.99
Vaccination with PCV7  
Unvaccinated (n = 177)  
Negative 77 (53.1) 68 (46.9)  
Positive 14 (43.7) 18 (56.3) 0.34
Vaccinated (n = 35)  
Negative 15 (60.0) 10 (40.0)  
Positive 7 (70.0) 3 (30.0) 0.71
Serotypes of PCV7b  
Positive for any PCV7 serotype 20 (51.3) 19 (48.7)  
Negative for PCV7 serotypes, but 
positive for S. pneumonia
1 (33.3) 2 (66.7) 0.99
Serotypes of PCV13b  
Positive for any PCV13 serotype 20 (50.0) 20 (50.0)  
Negative for PCV13 serotypes, 
but positive for S. pneumonia
1 (50.0) 1 (50.0) 0.99
Specific serotypesc  
Negative for serotype 5 104 (51.5) 98 (48.5)  
Positive for serotype 5 9 (90.0) 1 (10.0) 0.02
Negative for serotype 19F 95 (53.7) 82 (46.3)  
Positive for serotype 19F 18 (51.4) 17 (48.6) 0.81
a Among S. aureus cases, 91.9% were methicillin-sensitive and 8.1% methicillin-resistant. Six patients were positive for staphylococcal cassette chro-
mosome mec.
bAmong 42 subjects positive for S. pneumoniae.
cOnly serotypes of S. pneumoniae for which at least 10 subjects were positive are presented in the Table.
PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
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information can led to more appropriate prophy-
lactic and therapeutic measures. Unfortunately, S. 
pneumoniae and S. aureus carriage and reciprocal 
interactions in children with severe chronic 
underlying disease have received poor attention in 
recent years. Only HIV-infected children have 
been studied with conflicting results. In a first 
cross-sectional study, it was indicated that no 
Table 3. Oropharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in 296 children with type 1 diabetes 
mellitus, also according to selected subgroups and S. pneumoniae serotypes.
S. pneumoniae S. aureus P value
 Negative Positivea  
n (row %) n (row %)
All subjects  
Negative 99 (66.9) 49 (33.1)  
Positive 86 (58.1) 62 (41.9) 0.12
Age subgroups  
6–9 years (n = 61)  
Negative 15 (65.2) 8 (34.8)  
Positive 21 (55.3) 17 (44.7) 0.44
10–14 years (n = 154)  
Negative 51 (71.8) 20 (28.2)  
Positive 47 (56.6) 36 (43.4) 0.051
15–17 years (n = 81)  
Negative 33 (61.1) 21 (38.9)  
Positive 18 (66.7) 9 (33.3) 0.63
Vaccination with PCV7b  
Unvaccinated (n = 174)  
Negative 54 (62.8) 32 (37.2)  
Positive 53 (60.2) 35 (39.8) 0.73
Vaccinated (n = 109)  
Negative 39 (73.6) 14 (26.4)  
Positive 30 (53.6) 26 (46.4) 0.03
Serotypes of PCV7c  
Positive for any PCV7 serotype 83 (57.6) 61 (42.4)  
Negative for PCV7 serotypes, 
but positive for S. pneumoniae
3 (75.0) 1 (25.0) 0.64
Serotypes of PCV13c  
Positive for any PCV13 serotype 83 (57.2) 62 (42.8)  
Negative for PCV13 serotypes, 
but positive for S. pneumoniae
3 (100.0) 0 (0.0) 0.26
Specific serotypesd  
Negative for serotype 4 166 (64.3) 92 (35.7)  
Positive for serotype 4 19 (50.0) 19 (50.0) 0.09
Negative for serotype 5 168 (62.7) 100 (37.3)  
Positive for serotype 5 17 (60.7) 11 (39.3) 0.84
Negative for serotype 9V 153 (61.7) 95 (38.3)  
Positive for serotype 9V 32 (66.7) 16 (33.3) 0.51
Negative for serotype 19A 176 (62.2) 107 (37.8)  
Positive for serotype 19A 9 (69.2) 4 (30.8) 0.77
Negative for serotype 19F 104 (66.7) 52 (33.3)  
Positive for serotype 19F 81 (57.9) 59 (42.1) 0.12
a Among S. aureus cases, 97.3% were methicillin-sensitive and 2.7% methicillin-resistant. Five patients were positive for staphylococcal cassette chro-
mosome mec.
bThirteen subjects were excluded due to missing information on PCV7 status.
cAmong 148 subjects positive for S. pneumoniae.
dOnly serotypes of S. pneumoniae for which at least 10 subjects were positive are presented in the Table.
PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
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association between pneumococcal and S. aureus 
colonisation could be demonstrated.21 More 
recently, a longitudinal study found that a lower 
prevalence of pneumococcal colonisation could 
lead to an increase in S. aureus presence in naso-
pharyngeal niche.22 This study adds some new 
information regarding older children with dis-
eases, such as asthma, CF and DM1, for whom 
several studies have evidenced an increased risk 
of development of both pneumococcal and staphy-
lococcal infections and for whom, at least in some 
cases, colonisation with these pathogens was 
expected to have a role in favouring the develop-
ment of disease itself or its worsening.
Asthmatic patients, independent of asthma 
severity, suffer from pneumococcal diseases more 
frequently then healthy subjects.10 Pneumococcal 
colonisation in the neonatal period is associated 
with frequent wheezing episodes in later paediatric 
life.22 Finally, S. aureus colonisation is more com-
mon in asthmatic patients23 and is associated with 
wheeze and asthma,24 possibly through the bacte-
rial enterotoxin sensitisation.25
In CF patients, S. aureus is a common coloniser 
of the respiratory tract and one of the most com-
mon pathogens responsible of the infective exacer-
bations and progressive decline of lung function.11 
Moreover, it has been recently demonstrated that 
children with this disease are frequently carriers of 
S. pneumoniae,2 and CF samples can have peculiar 
characteristics that can lead to increased virulence 
and significant lung damage.2 Colonising pneumo-
cocci form well-organised biofilm communities in 
the nasopharyngeal environment, with bacteria 
that are resistant to commonly prescribed anti-
pneumococcal antibiotics. Recent studies have 
shown that changes in the nasopharyngeal environ-
ment caused by concomitant virus infection, modi-
fications in the microflora, inflammation or other 
host assaults trigger active release of pneumococci 
from biofilms.26,27 These dispersed bacteria have 
distinct phenotypic properties and transcriptional 
profiles different from both biofilm and broth-
grown, planktonic bacteria, resulting in a signifi-
cantly increased virulence in vivo.27
The higher risk of pneumococcal infections, 
including IPD, in DM1 patients compared with 
healthy subjects has been well known for many 
years and was recently confirmed by the observa-
tion that, despite the introduction of vaccine proph-
ylaxis, it remained three times higher in the UK 
than in the general population.28–30 Finally, the 
incidence of staphylococcal infections in DM1 
patients is not marginal and some of them can be 
particularly severe and difficult to treat.31
Regarding pneumococcal colonisation, this 
study shows that in all the study groups it decreases 
with age. This is not surprising because a decline 
of pneumococcal colonisation from infancy to ado-
lescence has been repeatedly reported in healthy 
children and mainly ascribed to the maturation of 
the immune system.8,32 However, the incidence of 
colonisation in the studied children was signifi-
cantly higher than that reported in other studies 
involving younger children.32 Host immune char-
acteristics and the greater sensitivity of the molec-
ular methods used in this study in comparison with 
cultural methods used in most of the studies carried 
out in healthy children could explain this finding. 
However, this finding deserves attention because it 
supports the use of prophylactic measures against 
pneumococcal infections for school-age children 
and adolescents with asthma, CF and DM1.33
Previous PCV7 vaccination did not influence 
either absolute pneumococcal carriage or carriage 
of pneumococcal serotypes included in the conju-
gate vaccine or in PCV13. Other studies have evi-
denced that PCV administration has a relevant 
impact on colonisation, significantly reducing car-
riage of serotypes included in the administered 
vaccine.34 However, these studies were carried out 
only a few months after vaccine use and the wan-
ing of vaccine-induced immunity with time could 
explain the finding, as already suggested by the 
data recently collected in healthy older children 
and adolescents.35 On the other hand, this could be 
a problem because the waning of immunity against 
carriage could favour the development of diseases 
due to the initial elimination of the same serotypes 
and suggests the use of further booster vaccine 
doses to maintain protection.33
Regarding S. aureus colonisation, it cannot be 
forgotten that, from a theoretical point of view, 
the presence of S. pneumoniae in the pharynx 
should reduce S. aureus carriage. S. pneumoniae 
produces hydrogen peroxide that inhibits S. 
aureus36 and can further reduce staphylococcal 
carriage through immune mediated mechanisms 
based on cross-reactive antibodies against com-
mon conserved dehydrogenases.37 Moreover, the 
expression of phosphorylcholine and neuramini-
dase production by S. pneumoniae may contribute 
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to competitive effects between these bacterial 
species.38 Finally, pneumococci containing pilus-
islands have been negatively associated with S. 
aureus colonisation.39
However, in this study in which the incidence of 
S. aureus colonisation was in line with what was 
previously reported in healthy older children,13 
pneumococcal colonisation was not associated with 
a reduced S. aureus colonisation. In asthmatic chil-
dren and in those with CF aged 6–9 years, pharyn-
geal positivity for S. pneumoniae was associated 
with an increase in S. aureus colonisation. In chil-
dren with DM1, the incidence of S. aureus carriage 
was similar in patients with or without pneumococ-
cal colonisation. Moreover, no impact of PCV7 
administration was evidenced in any of the groups. 
These findings are in contrast with those reported in 
healthy subjects who displayed a negative relation-
ship between S. pneumoniae and S. aureus and a 
positive effect of PCV7 administration in condi-
tioning S. aureus carriage.35 The lack of a negative 
interaction between the two pathogens is difficult to 
explain. Bacterial colonisation with a single infec-
tious agent depends on several factors. Host 
defences, environmental factors, and carriage of 
other bacteria and/or viruses may play a role. The 
importance of direct bacterial effectors, viral-
induced bacterial adhesion, viral-derived disruption 
of the respiratory epithelium, production of viral 
products, and interference with the host immune 
system in conditioning type and degree of colonisa-
tion has been demonstrated.38 All of these factors 
were not evaluated, and it is possible that their role 
could have influenced S. pneumoniae and S. aureus 
colonisation of the studied children. The interfer-
ence of other unknown factors in conditioning car-
riage is also supported by the data regarding PCV7 
administration and S. aureus colonisation, which 
contrast with the data from in healthy younger chil-
dren. Previous studies have found that younger 
children who were colonised by primarily PCV7 
serotypes were less frequent carriers of S. aureus 
compared with subjects colonised with other sero-
types,9 suggesting that the serotypes included in 
PCV7 could protect against S. aureus colonisation. 
In this study, children who had received PCV7 sev-
eral years before were colonised by the same sero-
types included in the vaccine, and despite this 
vaccination, they were frequently colonised by S. 
aureus. The waning of immune protection against 
pneumococcal colonisation some years after the 
last vaccine dose has been already demonstrated in 
healthy children35 and can be the cause of the per-
sistence of carriage of PCV7 serotypes in the chil-
dren enrolled in this study despite previous 
vaccination. Finally, with very few exceptions, S. 
aureus was not associated with any of the serotypes 
included in both PCV7 and PCV13, confirming that 
in this study S. pneumoniae and S aureus colonisa-
tion were completely independent.
In conclusion, this study shows for the first time 
that school-age children and adolescents with 
asthma, CF and DM1 are frequently colonised by S. 
pneumoniae and S. aureus and that no negative 
relationship seems to exist between these patho-
gens. It is not known whether this colonisation 
depends on the immune characteristics and the 
infectious history of these patients or from other 
previously unidentified factors. Moreover, the sup-
posed protection offered by PCV7 administration 
against S. aureus colonisation was not demonstrated 
and no substantial association between single pneu-
mococcal serotypes and S. aureus was evidenced. 
Further studies are needed to clarify the relation-
ships between bacterial pathogens and the role of 
PCV in conditioning staphylococcal colonisation.
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